CRISPR Therapeutics AG (CRSP) Non Operating Income (2015 - 2026)

CRISPR Therapeutics AG has disclosed Non Operating Income across 12 years of filings, most recently posting $8.2 million for Q1 2026.

• Non Operating Income for Q1 2026 came in at $8.2 million, down 39.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $81.2 million (down 12.39% YoY), and the FY2025 annual result was $86.6 million, down 16.65% from the prior year.
• Non Operating Income came in at $8.2 million for Q1 2026 at CRISPR Therapeutics AG, down from $24.8 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $28.0 million in Q4 2024 to a low of $363000.0 in Q1 2022.
• The 5-year median for Non Operating Income is $20.0 million (2023), against an average of $17.2 million.
• Across the five-year window, Non Operating Income sank 81.43% in 2022 and soared 3410.19% in 2023, its largest moves.
• CRISPR Therapeutics AG's Non Operating Income stood at $11.5 million in 2022, then soared by 74.04% to $20.0 million in 2023, then jumped by 39.91% to $28.0 million in 2024, then retreated by 11.48% to $24.8 million in 2025, then plunged by 67.07% to $8.2 million in 2026.
• The last three Non Operating Income figures came in at $8.2 million (Q1 2026), $24.8 million (Q4 2025), and $26.2 million (Q3 2025), per Business Quant data.